Digital weight reduction firm Noom introduced its business enterprise, Noom for Work, is partnering with Liviniti, a nationwide pharmacy profit supervisor, to supply plan sponsors and their workers a digital GLP-1 Companion for power weight situations.
GLP-1s, or glucagon-like peptide-1 receptor agonists, are a category of medicines used within the remedy of sort 2 diabetes and, extra not too long ago, within the administration of power weight situations.
Noom’s GLP-1 Companion integrates with PBM processes, providing diet steerage and fitness-focused classes.
Its digital entrance door and medical triage determine members whose weight impacts their well being, serving to direct sources most appropriately to the highest-risk members.
Members who join Noom obtain a tailor-made GLP-1 Companion program once they point out they take a GLP-1 throughout onboarding. They may also have entry to a protein-tracking software, personalized and interactive mini-courses, fitness-focused classes and movies for folks in any respect exercise ranges.
They will additionally set objectives to help efficiently really fizzling out GLP-1s as clinically acceptable as they navigate their weight reduction journey.
“Enhancing all our weight reduction and weight problems care applications with our GLP-1 Companion ensures anybody taking a GLP-1 will now have entry to a tailor-made, built-in program that helps construct higher, lasting habits with way of life, diet, train and training to enhance a member’s long-term success whereas on treatment,” Dr. Linda Anegawa, chief of medication at Noom, mentioned in an announcement.
THE LARGER TREND
Healthcare stakeholders pointed to the rise of GLP-1 drugs to deal with power weight points as one of many key developments in healthcare final 12 months.
In October, Noom announced the enlargement of its digital enterprise providing, Noom for Work, to incorporate medical weight problems administration resolution Noom Med, which provides people entry to clinicians with obesity-care coaching who present personalized weight-loss plans and help for sufferers in lowering their reliance on GLP-1 medicines.
In 2021, Noom scored a whopping $540 million in Series F funding in 2021 and $58 million simply two years earlier.
Nonetheless, the digital weight-loss firm was not proof against the in depth workforce reductions inside digital well being firms in 2022, asserting two rounds of layoffs that 12 months.
In 2023, the corporate introduced a third round of job cuts, reportedly shedding a couple of quarter of its coaches.
Noom has made quite a few govt adjustments and appointments throughout the previous 12 months.
In July, the corporate introduced its CEO and cofounder, Saeju Jeong, stepped down after 16 years however would proceed as govt chairman of the board. Geoff Cook dinner was appointed as its new CEO and a member of the corporate’s board of administrators.
Final month, Noom announced the appointment of a brand new chief monetary officer, basic counsel and chief know-how officer.
